UMIN-CTR History
Name： UMIN ID：
| Unique ID issued by UMIN | UMIN000031584 |
|---|---|
| Receipt number | R000035952 |
| Scientific Title | Phase III study of ramucirumab plus docetaxel versus atezolizumab for PD-L1-negative or weakly positive advanced non-small-cell lung cancer after disease progression on platinum-based therapy. (EMERALD study) (WJOG10317L) |
| Date of disclosure of the study information | 2018/03/05 |
| Last modified on | 2022/11/22 10:03:04 |
| No. | Disposal | Last modified on | Item of update | |
|---|---|---|---|---|
| 1 | Insert | 2018/03/05 14:12:08 | ||
| 2 | Update | 2018/03/05 16:09:37 | Key inclusion criteria |
|
| 3 | Update | 2018/03/27 18:06:49 | Anticipated trial start date |
|
| 4 | Update | 2019/03/06 09:25:45 | Recruitment status |
|
| 5 | Update | 2019/09/06 09:09:52 | Date of IRB Last follow-up date |
|
| 6 | Update | 2020/03/06 09:08:33 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Address Last name of contact person Last name of contact person Zip code Address Organization Organization Address Address Tel |
|
| 7 | Update | 2020/04/01 09:06:49 | Recruitment status |
|
| 8 | Update | 2022/11/22 10:03:04 | Recruitment status |
